NCT06233877Not yet recruitingPhase 2
Clinical Trial Evaluating Low Dose G-FLIP Plus Mitomycin C for Stage IV Pancreatic Cancer
An Open Label Phase 2 Trial to Evaluate the Safety, Tolerability, and Efficacy of Low Dose G-FLIP in Combination With Mitomycin C in Patients With Stage IV Pancreatic Cancer Who Have Failed First-Line Treatment
Source: ClinicalTrials.gov · Last updated 28 Feb 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The study focuses on advanced metastatic pancreatic cancer, testing a combination of low-dose anti-cancer drugs (G-FLIP: Gemcitabine, Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin) with the addition of Mitomycin C. The aim is to find a safer and more effective therapy for this devastating disease.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 10 Jan 2024
- Start date
- 15 Mar 2024
- Primary completion date
- 31 Jan 2027
- Lead sponsor
- Hirschfeld Oncology
- Diseases
- Pancreatic cancer
- NCT number
- NCT06233877
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 60
- From 15 Mar 2024 to the primary completion date, 31 Jan 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- • Known brain metastases.
- Significant cardiovascular or other uncontrolled diseases.
- Pregnant or breastfeeding women
Who the study is looking for
- Histologically confirmed metastatic (Stage IV) pancreatic adenocarcinoma.
- Failed first-line chemotherapy.
- ECOG performance status of 0-2.
- Expected survival of more than 3 months.
- Adequate organ function as indicated by lab values.
- Age 18 or older.
- Signed informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hirscheld Oncology Coordinator of this site? Confirm its status | Brooklyn | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.